Stock Track | Apellis Pharmaceuticals Plummets 6.90% Intraday on Q4 Earnings Miss and Widening Losses

Stock Track02-24 22:35

Apellis Pharmaceuticals Inc. (NASDAQ: APLS) saw its stock price plummet 6.90% during Tuesday's intraday trading session.

The sharp decline followed the release of the company's fourth-quarter 2025 financial results, which revealed a significant earnings miss. Apellis reported a quarterly loss of $0.47 per share, which fell 23.36% short of the analyst consensus estimate for a loss of $0.38 per share. This result represents a 62.07% increase in losses compared to the $0.29 per share loss reported in the same period last year.

While quarterly sales of $199.913 million slightly exceeded the $199.222 million estimate, revenue declined by 5.94% year-over-year. The company reported a net loss of $58.951 million and an operating loss of $51.142 million for the quarter, contributing to investor concerns over the company's profitability.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1117776674?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 22:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117776674","market":"us","top_or_hot":-1,"title":"Stock Track | Apellis Pharmaceuticals Plummets 6.90% Intraday on Q4 Earnings Miss and Widening Losses","media":"Stock Track","content":"<p>Apellis Pharmaceuticals Inc. (NASDAQ: APLS) saw its stock price plummet 6.90% during Tuesday's intraday trading session.</p><p>The sharp decline followed the release of the company's fourth-quarter 2025 financial results, which revealed a significant earnings miss. Apellis reported a quarterly loss of $0.47 per share, which fell 23.36% short of the analyst consensus estimate for a loss of $0.38 per share. This result represents a 62.07% increase in losses compared to the $0.29 per share loss reported in the same period last year.</p><p>While quarterly sales of $199.913 million slightly exceeded the $199.222 million estimate, revenue declined by 5.94% year-over-year. The company reported a net loss of $58.951 million and an operating loss of $51.142 million for the quarter, contributing to investor concerns over the company's profitability.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Apellis Pharmaceuticals Plummets 6.90% Intraday on Q4 Earnings Miss and Widening Losses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Apellis Pharmaceuticals Plummets 6.90% Intraday on Q4 Earnings Miss and Widening Losses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-24 22:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Apellis Pharmaceuticals Inc. (NASDAQ: APLS) saw its stock price plummet 6.90% during Tuesday's intraday trading session.</p><p>The sharp decline followed the release of the company's fourth-quarter 2025 financial results, which revealed a significant earnings miss. Apellis reported a quarterly loss of $0.47 per share, which fell 23.36% short of the analyst consensus estimate for a loss of $0.38 per share. This result represents a 62.07% increase in losses compared to the $0.29 per share loss reported in the same period last year.</p><p>While quarterly sales of $199.913 million slightly exceeded the $199.222 million estimate, revenue declined by 5.94% year-over-year. The company reported a net loss of $58.951 million and an operating loss of $51.142 million for the quarter, contributing to investor concerns over the company's profitability.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APLS","symbol_name":"Apellis Pharmaceuticals Inc.","start_time":0,"source_url":"","article_id":"1117776674","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117776674","pubTimestamp":1771943726,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Apellis Pharmaceuticals Inc. (NASDAQ: APLS) saw its stock price plummet 6.90% during Tuesday's intraday trading session.The sharp decline followed the release of the company's fourth-quarter 2025...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"APLS":"Apellis Pharmaceuticals Inc."},"translate_title":"个股追踪|Apellis Pharmaceuticals盘中暴跌6.90%因Q4盈利未达预期且亏损扩大","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APLS":1},"content_text":"Apellis Pharmaceuticals Inc. (NASDAQ: APLS) saw its stock price plummet 6.90% during Tuesday's intraday trading session.The sharp decline followed the release of the company's fourth-quarter 2025 financial results, which revealed a significant earnings miss. Apellis reported a quarterly loss of $0.47 per share, which fell 23.36% short of the analyst consensus estimate for a loss of $0.38 per share. This result represents a 62.07% increase in losses compared to the $0.29 per share loss reported in the same period last year.While quarterly sales of $199.913 million slightly exceeded the $199.222 million estimate, revenue declined by 5.94% year-over-year. The company reported a net loss of $58.951 million and an operating loss of $51.142 million for the quarter, contributing to investor concerns over the company's profitability.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1117776674","isCrawlerRequest":true}